Shiftconnector Artificial Manufacturing Intelligence by eschbach Wins Platinum Pinnacle Technology Award
BOSTON, July 17, 2025 /PRNewswire/ — Global software leader eschbach has won the prestigious Platinum Pinnacle Technology Award in the Productivity and Collaboration Tools category. This achievement underscores the revolutionary advancements of their Shiftconnector® platform, particularly the AI-driven Shiftconnector® Artificial Manufacturing Intelligence (SAMI®), which is transforming the process industry.
The Pinnacle Technology Award recognizes groundbreaking developments and solutions that push the boundaries of innovation and enhance everyday experiences across industries. This prestigious honor celebrates those who are redefining how we work, connect, and solve problems through transformative technology. In the manufacturing sector, eschbach's Shiftconnector® stands out as a powerful example—enhancing the daily workflows of operators by making critical data more accessible, actionable, and intuitive than ever before.
With its latest enhancements, SAMI transforms how pharmaceutical and chemical manufacturing teams interact with operational data. By integrating Generative AI (GenAI) into a conversational interface, SAMI empowers users to ask questions in natural language and receive instant, contextual insights—dramatically improving decision-making speed and accuracy.
'By combining advanced AI with intuitive visualization tools, we've created a seamless way for teams to access and act on critical information,' said Andreas Eschbach, Founder and CEO of eschbach. 'This award validates our commitment to making manufacturing collaboration smarter, faster, and more human-centric.'
Kate Lang, Executive Director of the Pinnacle Awards, emphasized eschbach's exceptional contribution: 'This award celebrates excellence in technology and leadership, particularly in how eschbach is redefining information access and problem-solving within manufacturing.'
The enhanced SAMI chat feature liberates users from traditional, time-consuming interfaces. Instead of navigating complex reports, employees can simply ask, 'What happened during last night's shift?' and receive a clear, traceable summary of events and actions.
Built on the robust capabilities of Smart Search and Smart Solutions, SAMI now delivers even greater precision, speed, and traceability—making it an indispensable tool for high-stakes environments in chemical and pharmaceutical production.
About eschbachWith its global headquarters in Bad Säckingen, Germany and its North America headquarters in Boston, MA, eschbach is the premier enterprise software developer for plant process management. Shiftconnector's AI-driven technology helps manufacturing teams take charge of plant operations, process safety, asset performance, and product quality. eschbach serves process industries and supports digital transformation, helping managers, operators, and technicians to achieve the highest level of team communications. The award-winning solution is trusted worldwide by leading manufacturing companies such as DuPont, Albemarle, BASF, Roche, and Bayer.
Media Contact – North AmericaDawn FontaineRipple Effect CommunicationsT: 617-536-8887dawn@rippleeffectpr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
WEBER RANCH VODKA INTRODUCES 'TEX,' A FIRST-OF-ITS KIND PERSONALIZED ARTIFICIAL INTELLIGENCE MIXOLOGIST
AI-Powered Experience, Delivered Through SMS or Online Chat, Inspires Creativity and Celebrates Cocktail Craftsmanship MUENSTER, Texas, Aug. 5, 2025 /PRNewswire/ — Weber Ranch 1902 Vodka, the innovative new vodka brand distilled exclusively from 100% Blue Weber Agave, has launched 'Tex,' a groundbreaking new tool that combines professional mixology expertise with the intelligence of AI – delivered right through SMS text or online chat – to help address consumers' ongoing frustration with how to craft and perfectly pair cocktails at home. Personified by an icon of a friendly Texan tipping his cowboy hat, Tex ('Your Weber Ranch AI Mixologist') leverages cutting-edge OpenAI technology to connect users instantly with a Weber Ranch virtual bartender trained on the knowledge of industry pros. It's a useful, functional, and remarkably individualized tool (not scripted) that highlights the versatility of Weber Ranch Vodka in cocktails, utilizing recipes that were created by bartenders across the country. By blending human creativity with AI precision, Tex is ready to recommend, guide, and personalize drink recipes anywhere, anytime. To use 'Tex,' simply text #AskTex to 1-940-400-1902 or click this LINK. And of course, 'Tex' is also available on the Weber Ranch Vodka website, 'While most companies and brands use AI simply for automated customer service 'chat,' we're doing something very different and innovative, harnessing the immense power of AI technology to create a first-of-its-kind personalized tool that deepens customer engagement in a way that is helpful, informative, and fun,' says Lee Applbaum, President and CEO of Texas-based Round 2 Spirits, the brand owner and creator of Weber Ranch Vodka. 'AI is replacing search, it's the way that people access and consume information today, and Tex delivers on that in an entertaining way, while also staying true to our respect and appreciation for the professional bartender's craft. Also, as we think about the future of Tex, and with the rise of Agentic AI, we clearly see a not-so-distant world where he not only makes recipe recommendations, but actually orders the ingredients for delivery to a consumer's home, or makes restaurant or bar reservations to enjoy a Weber Ranch cocktail.' Tex was built for real-world, real-life behavior. For example, users can snap a photo of the items inside their refrigerator or pantry, text it to Tex, and immediately get a cocktail recipe suggestion, using ingredients on-hand. Tex can also direct people to a bar or retail store, or answer questions about batching recipes, planning a cocktail menu for a special occasion, personalizing cocktail names for a friend's birthday party, find alternative ingredients, or virtually anything else that someone might want to ask about bartending and cocktails or brand and category information. Because Tex isn't scripted, the exact way he phrases answers will be different each time. Over 70 percent of Tex's logic is powered by ChatGPT, not just for conversation, but for core application logic. Development of the tool will never be completed, it will only continue to get better and smarter as more people engage with it, and those engagements over time help improve Tex's reasoning, and his answers. 'Most bots just talk. Ours thinks,' says James Penfold, co-founder and Experience Director at New York and London-based Cyphr, the digital-first experience and venture studio that partnered with the Weber Ranch team to master the technology behind Tex. 'Tex isn't just answering questions, he's learning what you like and adapting. The more you interact, the more personalized your experience becomes – just like talking to your favorite bartender who remembers your favorite drink.' This digital-first approach to marketing is baked into Weber Ranch's ethos of innovation. Not only has the brand disrupted the vodka category by creating a vodka distilled from agave (whereas most other vodkas are made from wheat, corn, or potato), from the day that Weber Ranch launched last year it has leveraged leading-edge technology for brand storytelling, social engagement, CRM, and ecommerce – and now AI. The team behind Weber Ranch Vodka previously created and led Patrón Tequila, a company that also had a proven history of harnessing the latest tech innovation for consumer engagement and marketing – from Oculus to augmented reality to Amazon Alexa, when those technologies were first introduced years ago. 'We're setting new standards for how brands engage with consumers, recognizing that innovation in our industry must extend well beyond the bottle to truly be meaningful,' says Applbaum. About Weber Ranch 1902 VodkaWhile most vodka is made from wheat, corn, or potato, Weber Ranch 1902 Vodka is distilled from 100% Blue Weber Agave to create an extraordinarily unique and clean taste profile full of bright citrus notes from the agave, and a velvety smooth mouthfeel not found in any other vodka. This incredibly unique spirit begins its journey in Jalisco, Mexico, where the agave is hand-harvested and distilled before being transported to the Weber Ranch Distillery in Muenster, Texas, where it is further distilled in proprietary copper pot and column stills, filtered, and bottled in an eye-catching and distinctive package. It is this second distillation and filtration in Texas, as well as the addition of water from the local Trinity Aquifer, that creates its unique character. Because Weber Ranch Vodka is exclusively crafted from agave, it is naturally 100% gluten, carb, and additive free from garden to glass. Weber Ranch Vodka was created by Round 2 Spirits, founded by the team who previously created and built Patrón Tequila into an iconic global brand. For more information, please visit
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Meet the Switchback: Aliner's Bold New Take on Rugged, Compact Camping
MOUNT PLEASANT, Pa., Aug. 5, 2025 /PRNewswire/ — Aliner, the original innovator in lightweight camping, proudly announces the launch of its newest product: the Aliner Switchback. Designed for the no-frills adventurer, the Switchback delivers exactly what overlanders, weekend warriors, and digital nomads have been craving — a cozy, insulated, ultra-light sleeping pod for your truck with zero fuss. 'No kitchen. No bathroom. No problem. The Switchback is all about the journey — and a great night's sleep when you get there,' says Brett Randall, President and CEO of Aliner. At just 375 lbs, the Switchback fits most standard and mid-sized pickup truck beds (5.5'–8′) and is garageable even when mounted, fitting through a 7′ garage door in the closed position. Whether you're fishing, hunting, hiking deep into the backcountry, or simply road-tripping light, this rugged aluminum-frame camper lets you go far and sleep well. Key Features Include: Ultra-Lightweight Build – 375 lbs of durable aluminum, zero wood = zero rot Comfort-First Interior – Full-size 60″ x 72″ bed, insulated walls, tinted safety glass Minimal Setup – 30-second setup for maximum relaxation Garage-Friendly – Fits into a standard garage while mounted Lockable Storage – Two 60″ long exterior storage drawers Secure Mounting – Quick tie-down system and lockable entry Electrical Feature – 30-amp converter with interior 12-volt and electric outlets The Switchback is the perfect option for anyone looking to strip camping down to its essentials — and enjoy nature without compromise. About Aliner: Aliner is the original manufacturer of A-frame camping trailers. Located in western Pennsylvania, Aliner is a top producer of folding campers. Founded in 1984, Aliner focuses on lightweight, garageable, camping trailers. 1297 KECKSBURG ROADMT. PLEASANT, PA (724) 237-5227 PRESS RELEASE CONTACT:JANA RANDALLPHONE: (724) 831-0232[email protected]
Malaysian Reserve
3 hours ago
- Malaysian Reserve
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under 'Events and Presentations' in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as 'may', 'will', 'should', 'would', 'expect', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'predict', 'potential', 'seem', 'seek', 'future', 'continue', or 'appear' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the 'Risk Factors' section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040
